Patent · US Active

Anti-SARS-COV-2 antibodies and uses thereof

US11365239B2 · kind B2 · utility

0Cited by

18References

15Claims

0Family size

Inventors

Zheng Zhang · Beijing, CN
Linqi Zhang · New York, US
Lei Liu · Thousand Oaks, US
Qi Zhang · Hangzhou City, CN
Bin JU · Shandong, CN
Xuanling SHI · Beijing, CN
Qing Zhu · Mansfield Center, US

Key dates

Filing date	Nov 19, 2020
Grant date	Jun 21, 2022
Priority date	—
Expiry date	Dec 6, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are modified anti-SARS-COV-2 antibodies or antigen binding fragments thereof having extended half life and optimized immune activities. Disclosed herein is also directed to pharmaceutical compositions comprising the same and a method for treating or preventing a disease in human patients that is caused by or related to the infection of SARS-COV-2.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.